Navigation Links
Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer
Date:3/18/2009

tion ratio.

"Zoticon is delighted that Sopherion Therapeutics LLC has accomplished its recruitment objectives for the Phase III registration trial in a timely and efficient manner, which can be directly attributed to the strength and quality of its management team," said Asher Nathan, Managing Director of Zoticon and Chairman of the Board of Sopherion Therapeutics LLC.

"Myocet has the potential to be a valued addition to the treatment of metastatic breast cancer," said Ronald H. Goldfarb, Ph.D., President and CEO of Sopherion Therapeutics. "We look forward to reporting the efficacy results from this clinical trial after the required period of follow-up."

About Myocet(TM) (Nonpegylated Liposomal Doxorubicin)

Myocet is a liposome-encapsulated doxorubicin-citrate complex. By encapsulating doxorubicin in a liposome -- a manufactured, microscopic, vesicle consisting of discreet aqueous compartments surrounded by membranes composed of naturally occurring fats -- its distribution in the body is altered in such a way as to reduce doxorubicin's toxicity. Extensive clinical studies of Myocet in women with breast cancer have shown that the cardiac toxicity of doxorubicin can be significantly reduced, while the efficacy of the drug is maintained. This delivery system does not encompass pegylation and yields very little hand foot syndrome

About Sopherion Therapeutics, LLC

Sopherion Therapeutics, LLC is a privately-held biotechnology company based in Princeton, New Jersey. The Company is focused on developing novel anti-cancer therapies for patients suffering from advanced cancer, particularly in the metastatic stage. Sopherion is dedicated to the acquisition, discovery, development and commercialization of novel anti-cancer therapies with unique therapeutic activities that address unmet medical needs in and extend human life. In 2004, Sopherion en
'/>"/>

SOURCE Sopherion Therapeutics, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sopherion Therapeutics Secures $55 Million in Series C Funding
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. FDA Accepts IND for Arno Therapeutics Pan-DAC / Akt Inhibitor, AR-42
4. Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA
5. United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso)
6. Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results
7. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
8. Michael J. Fox Foundation Commits Up To $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
9. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
10. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 16
11. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Xeno Diagnostics has again received an ... COLA inspection. Xeno has met all criteria for ... organization. Accreditation is earned only by laboratories that ... demonstrate continued accuracy in the performance of proficiency ... , While the Laboratory Excellence award ...
(Date:12/17/2014)... Audacity, a leading California-based health and science ... Huntsworth Health Group, is proud to announce the addition ... role, Gonzales will serve as Senior Vice President of ... welcome a talent of Jamie’s caliber to the Audacity ... is a proven healthcare innovation leader and brand management ...
(Date:12/17/2014)... Dec. 17, 2014  United Therapeutics Corporation (NASDAQ: ... as well as changes to Martine Rothblatt , ... United Therapeutics announced the promotion of ... Executive Officer and David Zaccardelli , Pharm.D. to ... with these promotions, Dr. Rothblatt,s title will change from ...
(Date:12/17/2014)... FRANCISCO, Calif. , Dec. 17, 2014 /PRNewswire/ ... of a Phase 2 study evaluating the investigational ... treatment of patients with severe, chronic itch who ... standard of care, including topical steroids and antihistamines. ... percent change in Visual Analog Scale (VAS) itch ...
Breaking Biology Technology:Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
... everything from explosives to tainted milk, materials for use ... by a University of Houston (UH) chemist and his ... "There are many dangerous substances, pollutants and ... Advincula, a highly cited materials scientist at UH. "Our ...
... February 7, 2011 -- A low cost, nanometer-sized drug ... burns, has been developed by a group of scientists from ... in the U.S. and Japan. Diabetes is a ... the world,s population. Poor blood circulation arising from diabetes often ...
... Feb. 16, 2011 / PRNewswire/ -- Sigma-Aldrich® ... following executive leadership appointments intended to more closely ... Frank Wicks, President Research, will assume ... including those in Research Essentials, Research Specialties and ...
Cached Biology Technology:Sensors to detect explosives, monitor food being developed at UH 2Sensors to detect explosives, monitor food being developed at UH 3Sigma-Aldrich Announces Organizational Changes 2Sigma-Aldrich Announces Organizational Changes 3
(Date:12/11/2014)... 2014  That blood pressure plays a role in human ... the medical term for high blood pressure – was first ... inflatable cuff that,s used in measuring blood pressure was invented ... new about hypertension, its triggers and its effects. In fact, ... and the best ways to treat it. For ...
(Date:12/10/2014)... YORK , Dec. 8, 2014 You,ve been ... banking account but can,t remember your password, site key or ... Who was your first grade teacher? Today, ... the app that will finally put an end ... – 1U TM . 1U leverages a user,s ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... for its School of Medicine. Funding for this $50 ... campaign that will be publicly launched next summer. ... in the former 60 series R.J. Reynolds Tobacco Company ... Construction will begin immediately with plans to be ready ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... plant geneticists and crop scientists has pioneered an economical ... boost levels of provitamin A, the precursors that are ... help to enhance the nutritional status of millions of ... is described this week in the journal Science. ...
... Genetic Alliance, an organization devoted to accelerating the translation ... healthcare, has named Genetic Testing as its official journal. Genetic ... Inc. ... Genetic Testing, says Sharon Terry, President and CEO of Genetic ...
... Australias extinct marsupial lion (Thylacoleo carnifex) would have made ... the two big hyper-carnivores ever squared off in a ... New research published in the Journal of Zoology ... type teeth to scissor through hide and flesh to ...
Cached Biology News:Team finds an economical way to boost the vitamin A content of maize 2Team finds an economical way to boost the vitamin A content of maize 3Genetic Alliance names Genetic Testing as its official journal 2Marsupial lion tops African lion in fight to death 2
... multi-purpose, high gel-strength agarose suitable for a ... conventional constant field to Pulsed Field Gel ... strength and exclusion limits, Multi ABgarose can ... running times. This in turn means reduced ...
Mouse monoclonal [1.F.1] to Yersinia pestis F1 antigen ( Abpromise for all tested applications). Antigen: Purified F1 antigen of Y. pestis vaccine strain EB....
Rabbit polyclonal to L Kynurenine ( Abpromise for all tested applications). Antigen: Synthetic peptide L Kynurenine conjugated to a protein carrier. Entrez Gene ID: 8942 Swiss Protein ID...
Rabbit polyclonal to P5 ( Abpromise for all tested applications). entrezGeneID: 10954 SwissProtID: Q14554...
Biology Products: